Literature DB >> 10906157

Lithium nephrotoxicity: a progressive combined glomerular and tubulointerstitial nephropathy.

Glen S Markowitz1, Jai Radhakrishnan2, Neeraja Kambham1, Anthony M Valeri2, William H Hines3, Vivette D D'Agati1.   

Abstract

This study examines the clinical features, pathologic findings, and outcome of 24 patients with biopsy-proven lithium toxicity. The patient population was 50% male, 87.5% Caucasian, and had a mean age of 42.5 yr (range, 26 to 57). Mean duration of lithium therapy for bipolar disorder was 13.6 yr (range, 2 to 25). All patients were biopsied for renal insufficiency (mean serum creatinine 2.8 mg/dl; range, 1.3 to 8.0), with associated proteinuria >1.0 g/d in 41.7%. Nephrotic proteinuria (>3.0 g/d) was present in 25%. Other features included nephrogenic diabetes insipidus in 87% and hypertension in 33.3%. Renal biopsy revealed a chronic tubulointerstitial nephropathy in 100%, with associated cortical and medullary tubular cysts (62.5%) or dilatation (33.3%). All of the renal cysts stained for epithelial membrane antigen, while 51.4% stained with lectin Arachis hypogaea, and only 3.8% stained with Tetragonolobus purpureas, indicating they originated from distal and collecting tubules. The degree of tubular atrophy and interstitial fibrosis was graded as severe in 58.3%, moderate in 37.5%, and mild in 4.2% of cases. There was a surprisingly high prevalence of focal segmental glomerulosclerosis (50%) and global glomerulosclerosis (100%), sometimes of equivalent severity to the chronic tubulointerstitial disease. The significant degree of foot process effacement (mean 34%, five of 14 cases with >50%) suggests a potential direct glomerular toxicity. Focal segmental glomerulosclerosis correlated with proteinuria >1.0 g/d (P = 0.0014, Fisher exact test). Despite discontinuation of lithium, seven of nine patients with initial serum creatinine values >2.5 mg/dl progressed to end-stage renal disease (ESRD). Only three patients, all with initial serum creatinine <2.1 mg/dl, had subsequent improvement in renal function. By Kaplan-Meier survival analysis, the only significant predictor of progression to ESRD was serum creatinine >2.5 mg/dl at biopsy (P = 0. 008). In conclusion, lithium nephrotoxicity primarily targets distal and collecting tubules, with a higher incidence of proteinuria and associated glomerular pathology than recognized previously. Renal dysfunction is often irreversible despite lithium withdrawal, and early detection is essential to prevent progression to ESRD.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10906157     DOI: 10.1681/ASN.V1181439

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  67 in total

1.  A possible interaction between lithium and rofecoxib.

Authors:  Jöns Lundmark; Tove Gunnarsson; Finn Bengtsson
Journal:  Br J Clin Pharmacol       Date:  2002-04       Impact factor: 4.335

2.  Will lithium damage my kidneys?

Authors:  Thomas J Raedler
Journal:  J Psychiatry Neurosci       Date:  2012-05       Impact factor: 6.186

3.  A case of renal failure requiring a renal transplant secondary to lithium treatment.

Authors:  Seema S Bora; Rohit Madan; Ashish Sharma
Journal:  Prim Care Companion CNS Disord       Date:  2012-02-16

4.  In Vitro and In Vivo Evidence on the Role of Mitochondrial Impairment as a Mechanism of Lithium-Induced Nephrotoxicity.

Authors:  Mohammad Mehdi Ommati; Hossein Niknahad; Omid Farshad; Negar Azarpira; Reza Heidari
Journal:  Biol Trace Elem Res       Date:  2020-07-25       Impact factor: 3.738

Review 5.  Remote ischemic preconditioning for kidney protection: GSK3β-centric insights into the mechanism of action.

Authors:  Zhangsuo Liu; Rujun Gong
Journal:  Am J Kidney Dis       Date:  2015-08-10       Impact factor: 8.860

6.  Elevated urinary ADAM12 protein levels in lithium-treated bipolar patients.

Authors:  C Nadri; Y Bersudsky; R H Belmaker; G Agam
Journal:  J Neural Transm (Vienna)       Date:  2006-10-27       Impact factor: 3.575

Review 7.  Molecular mechanisms in lithium-associated renal disease: a systematic review.

Authors:  Soham Rej; Shamira Pira; Victoria Marshe; André Do; Dominique Elie; Karl J Looper; Nathan Herrmann; Daniel J Müller
Journal:  Int Urol Nephrol       Date:  2016-06-29       Impact factor: 2.370

8.  Undiagnosed Bipolar Disorder: New Syndromes and New Treatments.

Authors:  Ira D Glick
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2004

Review 9.  A systematic review and combined meta-analysis of concentration of oral amisulpride.

Authors:  Lin Li; Lu Li; De-Wei Shang; Yu-Guan Wen; Yu-Ping Ning
Journal:  Br J Clin Pharmacol       Date:  2020-03-03       Impact factor: 4.335

Review 10.  Lithium in the Kidney: Friend and Foe?

Authors:  Mohammad Alsady; Ruben Baumgarten; Peter M T Deen; Theun de Groot
Journal:  J Am Soc Nephrol       Date:  2015-11-17       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.